Difelikefalin
High EvidenceDifelikefalin (Korsuva in the U.S., Kapruvia in Europe) is a synthetic tetrapeptide built entirely from D-amino acids - D-Phe-D-Phe-D-Leu-D-Lys capped with a 4-aminopiperidine-4-carboxylic acid - that acts as a selective agonist at the kappa opioid receptor. Its defining property is what it cannot do: the molecule is hydrophilic and bulky enough that it does not meaningfully cross the blood-brain barrier, so it reaches kappa receptors on peripheral sensory nerve endings, keratinocytes and immune cells while leaving the central kappa receptors that produce dysphoria and hallucinations largely untouched. It has no activity at the mu opioid receptor, so it carries neither euphoria nor respiratory depression. In the Phase 3 KALM-1 and KALM-2 trials in hemodialysis patients with moderate-to-severe chronic-kidney-disease-associated pruritus, roughly 40-51% of difelikefalin-treated patients achieved a clinically meaningful (>=3-point) reduction on the 10-point Worst Itching Intensity NRS at 12 weeks versus roughly 20-28% on placebo. The FDA approved intravenous difelikefalin in August 2021; the EU approved it as Kapruvia in April 2022.
What It Is
Difelikefalin is the drug that answers a question opioid pharmacology had been circling for decades: what happens if you build an opioid agonist that physically cannot get into the brain? Kappa opioid receptor agonists have been known to suppress itch and pain since the 1980s, but every clinically tested compound in the class was also centrally active, and central kappa activation produces dysphoria, sedation, depersonalization and hallucinations severe enough to end most programs. Difelikefalin solves this structurally rather than pharmacologically. It is a tetrapeptide of four D-amino acids - D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl - terminating in a 4-aminopiperidine-4-carboxylic acid group, formally 4-amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)piperidine-4-carboxylic acid. The all-D backbone makes it resistant to the proteases that would shred an L-amino-acid tetrapeptide, and the combination of high hydrophilicity, charge and bulk makes it a poor substrate for passive CNS entry. The result is a molecule that is a genuine opioid at the receptor level and a peripherally restricted agent at the organism level. Because it never reaches central mu receptors - and in fact has no meaningful mu activity anywhere - it does not produce euphoria, does not cause respiratory depression at supratherapeutic doses, and did not produce opioid withdrawal on discontinuation in trials. The clinical target is chronic kidney disease-associated pruritus, or CKD-aP, an underrecognized and severely undertreated problem in hemodialysis. Dialysis itch is not a histamine-mediated condition, which is why antihistamines routinely fail and why gabapentin is used off-label with mixed results. The prevailing model implicates an imbalance between mu and kappa opioid tone in the skin and dorsal horn, plus a peripheral inflammatory component. Difelikefalin targets both arms: kappa activation on peripheral C-fiber terminals dampens the afferent itch signal, and kappa activation on monocytes, T lymphocytes and keratinocytes reduces release of pro-inflammatory mediators. The pivotal evidence comes from KALM-1 (NCT03422653) and KALM-2 (NCT03636269), both randomized, double-blind, placebo-controlled Phase 3 trials in adults on hemodialysis, dosing 0.5 mcg/kg as an intravenous bolus into the venous line of the dialysis circuit three times weekly after each session for 12 weeks. KALM-1 was published in the New England Journal of Medicine in January 2020. Across the program, approximately 40-51% of treated patients reached the primary endpoint of a >=3-point improvement on the Worst Itching Intensity Numerical Rating Scale versus approximately 20-28% on placebo, with parallel improvements in itch-related quality of life. The effect size is real but partial - this is a drug that meaningfully reduces itch in a substantial minority of a population with few alternatives, not one that abolishes it. The pharmacokinetics are unusually clean for a peptide in this setting: 100% bioavailability by the intravenous route, a volume of distribution around 238 mL/kg, plasma protein binding of 23-28%, no cytochrome P450 metabolism at all, and excretion of unchanged drug in urine and bile, with an elimination half-life near 2 hours and a duration of effect around 12 hours. In dialysis patients on extensive polypharmacy, the absence of CYP interactions is a practical advantage rather than a footnote. An oral formulation was carried forward separately. Oral difelikefalin showed activity in Phase 2 in CKD-associated pruritus and, more notably, in the KOMFORT trial in notalgia paresthetica - a localized neuropathic itch of the upper back with no approved therapy - published in the New England Journal of Medicine in February 2023, in which 126 patients received 2 mg twice daily or placebo for 8 weeks. The atopic dermatitis program did not survive: in December 2023, dose-finding Part A of KIND-1 showed that oral difelikefalin added to topical corticosteroids produced no meaningful benefit over topical corticosteroids alone, and that indication was discontinued. Cara Therapeutics, the originating company, subsequently narrowed to the notalgia paresthetica program and then merged into Tvardi Therapeutics in 2025; commercial rights to the approved intravenous product sit with Vifor Fresenius Medical Care Renal Pharma and CSL Vifor, and Kapruvia has been recommended by NICE for NHS use in England.
Regulatory Status
Korsuva (difelikefalin) injection was approved by the FDA in August 2021 for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. It is administered as a 0.5 mcg/kg intravenous bolus into the venous line of the dialysis circuit at the end of each hemodialysis session, three times weekly, using the patient's prescribed dry body weight. The European Commission approved the same molecule as Kapruvia in April 2022, and additional approvals include the UK, Switzerland, Canada, Australia and several other markets. Difelikefalin is a scheduled-drug-adjacent opioid receptor agonist dispensed under clinical supervision in a dialysis setting; it is not a supplement, a research chemical, or a product available for self-administration, and it has not been studied in peritoneal dialysis or in pediatric patients.
Effective: August 2021
View FDA SourceWhy Researchers Study It
Difelikefalin is the clearest existing proof that peripheral restriction is a viable design strategy for opioid drugs rather than a theoretical one. The kappa receptor has been an attractive analgesic and antipruritic target for forty years, and the obstacle has never been efficacy - it has been that central kappa activation causes dysphoria and hallucinations. By building the agonist as a bulky, hydrophilic, all-D-amino-acid tetrapeptide, difelikefalin keeps the target and discards the compartment, and the resulting clinical profile is measurably different from every earlier kappa agonist. That makes it a template question for peptide chemists: which other centrally intolerable targets become drugable if the ligand is engineered out of the brain? Second, it is one of the few drugs to validate a non-histaminergic model of chronic itch in humans. Dialysis pruritus does not respond to antihistamines because histamine is not driving it; the fact that a peripherally restricted kappa agonist works is direct clinical evidence for the opioid-imbalance and neuro-immune models of itch, and it is why the same mechanism was tested in neuropathic itch conditions such as notalgia paresthetica. Third, the pharmacokinetics are instructive for anyone thinking about peptides in renal disease. Difelikefalin is not metabolized by any cytochrome P450 enzyme, is only 23-28% protein-bound, and is excreted unchanged - in a population taking a dozen concurrent medications, that profile is close to ideal, and it illustrates why small hydrophilic peptides can be easier to place in polypharmacy settings than small molecules. Fourth, the safety data are a genuinely useful reference point for opioid pharmacology: a dedicated randomized trial at supratherapeutic doses of 1.0 and 5.0 mcg/kg found no respiratory depression, and no opioid withdrawal was observed on cessation, which supports the claim that mu-receptor silence rather than partial agonism is what removes those risks. Finally, the program's failures are as informative as its success - the KIND-1 atopic dermatitis result showed that peripheral kappa agonism does not rescue itch that is already being addressed by topical anti-inflammatory therapy, which sharpens rather than weakens the mechanistic story.
Proposed Mechanisms
- Synthetic tetrapeptide of four D-amino acids (D-Phe-D-Phe-D-Leu-D-Lys) terminating in a 4-aminopiperidine-4-carboxylic acid group; the all-D backbone confers protease resistance and the hydrophilic, bulky, charged structure prevents meaningful blood-brain barrier penetration
- Selective agonist at the kappa opioid receptor with no meaningful activity at the mu opioid receptor, eliminating euphoria, abuse potential and respiratory depression
- Activates kappa receptors on peripheral sensory C-fiber terminals in the dermis, reducing afferent itch and nociceptive signaling toward the central nervous system
- Activates kappa receptors on immune cells - monocytes, T lymphocytes, macrophages, mast cells - and on keratinocytes, reducing release of pro-inflammatory mediators including prostaglandins
- Addresses the mu/kappa opioid tone imbalance implicated in uremic pruritus, a non-histaminergic itch pathway that explains why antihistamines are ineffective in this population
- Pharmacokinetically inert with respect to drug interactions: not metabolized by CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A; excreted unchanged in urine and bile; 23-28% plasma protein binding; elimination half-life approximately 2 hours with roughly 12 hours duration of action after a single intravenous dose
- Peripheral restriction is incomplete for one documented effect: diuresis appears to be produced through a central kappa pathway in rodent studies, indicating the barrier exclusion is functional rather than absolute
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Phase 3 (KALM-1, NCT03422653) - randomized, double-blind, placebo-controlled | Adults on hemodialysis with moderate-to-severe CKD-associated pruritus, difelikefalin 0.5 mcg/kg intravenously three times weekly after dialysis versus placebo for 12 weeks | Significantly more patients achieved the primary endpoint of a >=3-point improvement from baseline on the 24-hour Worst Itching Intensity NRS at week 12 versus placebo, with improvements in itch-related quality of life. Published in the New England Journal of Medicine, January 2020 | Source |
| Phase 3 (KALM-2, NCT03636269) - global randomized, double-blind, placebo-controlled | Hemodialysis patients with moderate-to-severe pruritus, difelikefalin 0.5 mcg/kg intravenously three times weekly versus placebo for 12 weeks | Confirmed the KALM-1 result in a separate global population. Across the Phase 3 program, approximately 40-51% of difelikefalin-treated patients achieved a >=3-point WI-NRS reduction at 12 weeks versus approximately 20-28% of placebo-treated patients | Source |
| Phase 3 pooled safety analysis | 848 subjects in placebo-controlled Phase 3 trials, including 278 aged 65 or older and 98 aged 75 or older | Most common adverse effects were diarrhea, vomiting, dizziness, somnolence, mental status changes and gait disturbances including falls; no overall difference in safety or efficacy by age, though somnolence was about 7 percentage points more common in older patients. Published in Kidney Medicine, 2022 | Source |
| Randomized, double-blind, placebo-controlled respiratory safety study | Healthy volunteers given supratherapeutic intravenous difelikefalin at 1.0 and 5.0 mcg/kg versus placebo | No respiratory depression: the lowest observed respiratory rate in either arm was 14 breaths per minute, well above the 10-breath threshold, with no significant difference in pulse oximetry. Transient paresthesia, hypoesthesia and somnolence occurred in 20-60% of participants and resolved within 90 minutes without intervention. Published in Clinical and Translational Science, 2021 | Source |
| Phase 2 (KOMFORT) - randomized, double-blind, placebo-controlled, oral formulation | 126 patients with moderate-to-severe pruritus due to notalgia paresthetica randomized to oral difelikefalin 2 mg twice daily (n=62) or placebo (n=63) for 8 weeks | Evaluated oral difelikefalin in a localized neuropathic itch condition with no approved therapy; supported advancement into a Phase 2/3 notalgia paresthetica program. Published in the New England Journal of Medicine, February 2023 | Source |
| Phase 2 dose-finding (KIND-1, Part A) - oral formulation, negative result | Patients with moderate-to-severe pruritus associated with atopic dermatitis, oral difelikefalin added to topical corticosteroids versus topical corticosteroids alone | Did not demonstrate meaningful clinical benefit over topical corticosteroids alone; the atopic dermatitis program was discontinued in December 2023. Safety and tolerability were consistent with prior trials | Source |
| Health technology assessment / cost-effectiveness | Difelikefalin versus standard care for CKD-associated pruritus in people with kidney failure receiving haemodialysis | Cost-effectiveness analysis published in PharmacoEconomics (2023) supported the NICE recommendation of Kapruvia for NHS use in England for adults with moderate-to-severe CKD-associated pruritus | Source |
Commonly Discussed Benefits
Researching Difelikefalin? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Difelikefalin is a prescription opioid receptor agonist administered intravenously into the dialysis circuit by clinical staff - it is not a wellness, recovery, longevity or performance peptide, has no legitimate self-administered use, and any product sold as difelikefalin outside a dialysis or pharmacy channel should be treated as unverified
- Dizziness, somnolence, mental status changes and gait disturbances including falls occur more often than with placebo and are the practical safety issue; patients should not drive or operate machinery until they know how the drug affects them, and fall precautions matter in older or frail patients
- Caution is required when combining difelikefalin with centrally acting depressants, sedating antihistamines or opioid analgesics, because the sedative effects are additive even though difelikefalin itself is peripherally restricted
- Diarrhea and vomiting are among the most common adverse effects and are not trivial in a dialysis population - dehydration, electrolyte imbalance and acid-base disturbance need to be actively monitored and corrected
- The approved indication is narrow: adults with moderate-to-severe CKD-associated pruritus who are undergoing hemodialysis. Difelikefalin has not been studied in patients on peritoneal dialysis, in pediatric patients, or in severe hepatic impairment, and is not recommended in those groups
- Efficacy is meaningful but partial. Roughly 40-51% of treated patients reached the >=3-point itch reduction threshold versus roughly 20-28% on placebo - a substantial improvement over an inadequate standard of care, not a cure, and expectations should be set accordingly
- The absence of euphoria, respiratory depression and withdrawal reflects the lack of mu-receptor activity and the peripheral restriction, but difelikefalin is still an opioid receptor agonist and long-term effects beyond the 8-to-12-week controlled trial periods remain uncharacterized
- Oral difelikefalin is not an approved product in any indication. The atopic dermatitis program was discontinued in December 2023, and the notalgia paresthetica program passed through Cara Therapeutics' 2025 merger into Tvardi Therapeutics - its current development status should be verified against primary sources rather than assumed
Comparisons
See how Difelikefalin compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus (KALM-1) - New England Journal of Medicine, January 2020 PubMed
- [2] Phase 2 Trial of Difelikefalin in Notalgia Paresthetica (KOMFORT) - New England Journal of Medicine, February 2023 PubMed
- [3] Difelikefalin - StatPearls, NCBI Bookshelf (structure, mechanism, dosing, pharmacokinetics, adverse effects) PubMed
- [4] Safety and Tolerability of Difelikefalin for Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program - Kidney Medicine, 2022 PubMed
- [5] Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: a randomized, double-blind, placebo-controlled trial - Clinical and Translational Science, 2021 PubMed
- [6] CR845-CLIN3103 (KALM-2): A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus - ClinicalTrials.gov NCT03636269 PubMed
- [7] Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus in People with Kidney Failure Receiving Haemodialysis - PharmacoEconomics, 2023 PubMed
- [8] Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND-1 Study Evaluating Oral Difelikefalin in Atopic Dermatitis (December 2023) PubMed
Keep researching in the app
- Log Difelikefalin to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
PT-141
High EvidenceA melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder in premenopausal women.
DSIP
Low EvidenceA neuropeptide studied for its role in sleep regulation and stress modulation.
KPV
Medium EvidenceA tripeptide derived from alpha-MSH, studied for anti-inflammatory and gut-protective properties.
LL-37
Medium EvidenceA human antimicrobial peptide studied for innate immunity, wound healing, and biofilm disruption.
Setmelanotide
High EvidenceA once-daily subcutaneous cyclic octapeptide melanocortin-4 receptor (MC4R) agonist, FDA-approved for several rare genetic and acquired forms of obesity that act through the leptin-melanocortin pathway.